A pharmacokinetic and pharmacodynamic study of delayed‐ and extended‐release hydrocortisone (Chronocort ^TM ) <i>vs.</i> conventional hydrocortisone (Cortef ^TM ) in the treatment of congenital adrenal hyperplasia

Abstract

Modified-release hydrocortisone represents a promising new treatment for CAH. Overnight adrenal androgens were well-controlled, but rose in the afternoon with once-daily dosing suggesting that a morning dose of glucocorticoid is needed. Further studies are needed to determine the optimal dosing regimen and long-term clinical outcome.